Importance Clinical research has shown that persistent negative beliefs maintain depression
and that subanesthetic ketamine infusions induce rapid antidepressant responses. Objective …

Rationale The N-methyl-d-aspartate (NMDA) glutamate receptor antagonist ketamine has
demonstrated rapid antidepressant effects in patients with treatment-resistant depression …

Background Ketamine has emerged as a rapid-acting antidepressant in treatment-resistant
depression (TRD) increasingly used in non-research, clinical settings. Few studies …

Background Ketamine demonstrated rapid antidepressant effects in treatment-resistant
depression (TRD). However, evaluation of ketamine's neurocognitive effect in TRD is …

Introduction Ketamine treatment prompts a rapid antidepressant response in treatment-
resistant depression (TRD). We performed an exploratory investigation of how ketamine …

Replicated evidence has documented cognitive deficits in populations with treatment-
resistant depression (TRD). Approximately 40% of patients with MDD present with …

Introduction: Ketamine has emerged as a rapid-acting antidepressant. While ongoing
treatment can prevent relapse, concerns exist regarding long-term exposure. Objective: We …

Background Recent studies have suggested that neurocognition is changed after repeated
infusions of ketamine in patients with treatment-resistant depression (TRD). The objective of …

The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine displays rapid
antidepressant effects in patients with treatment-resistant depression (TRD); however, the …

Background Clinical and animal studies have reported conflicting results regarding the effect
of ketamine on cognitive function, although increasing evidence supports a rapid and …